Regeneron Pharmaceuticals

Regeneron had a successful second quarter surpassing Wall Street expectations on all counts with noteworthy performance in every segment. The company made considerable pipeline progress in addition to having good commercial execution, with 3 regulatory approvals, 2 accepted regulatory filings, and 1 positive Phase III readout. They also completed the purchase of Checkmate Pharmaceuticals from Sanofi. Besides, in Q3, they acquired the global rights to Libtayo from Sanofi. The management believes these transactions will strengthen Regeneron’s oncology business over the short, medium, and long term. After five years and more than 450,000 patients treated since its launch, Dupixent is still expanding at a good rate. As a result of its unique clinical profile and capacity to successfully treat patients with type 2 inflammatory diseases, global and net product sales in Q2 totalled $2.1 billion, an increase of 43% at constant exchange rates over the same period last year. Based on this result, the management intends to add a third first-in-class indication for Dupixent later this year in patients with prurigo nodularis. Overall, we give the company a ‘Hold’ rating with a revised target price.